{"id":"NCT00501631","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","officialTitle":"Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2011-01","completion":"2011-03","firstPosted":"2007-07-16","resultsPosted":"2011-04-13","lastUpdate":"2011-09-22"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"VIVITROL 380 mg","otherNames":["naltrexone for extended-release injectable suspension","Medisorb naltrexone"]},{"type":"DRUG","name":"Placebo for VIVITROL 380 mg","otherNames":[]}],"arms":[{"label":"VIVITROL 380 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo for VIVITROL 380 mg","type":"PLACEBO_COMPARATOR"}],"summary":"VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. This Phase 3B trial was designed to evaluate the efficacy and safety of VIVITROL versus placebo. Injections were administered to patients in whom abstinence was enforced by a period of inpatient hospitalization of 7 to 21 days.","primaryOutcome":{"measure":"Cumulative Percentage of Participants by Heavy Drinking Rate","timeFrame":"up to 12 weeks","effectByArm":[{"arm":"Vivitrol","deltaMin":40.8,"sd":null},{"arm":"Placebo","deltaMin":47.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.336"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":152},"commonTop":["Injection site pain","Alcoholism","Headache","Nasopharyngitis","Nausea"]}}